Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Ketamine Hydrochloride in Laryngeal Neoplasms: NCT07746115 Clinical Landscape Report 2026
9 min read
Ketamine Hydrochloride in Laryngeal Neoplasms: NCT07746115 Clinical Landscape Report 2026
28 September 2026
NCT07746115 clinical landscape for Laryngeal Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Albumin-Bound Paclitaxel in Hypopharyngeal Carcinoma: NCT07752394 Clinical Landscape Report 2026
9 min read
Albumin-Bound Paclitaxel in Hypopharyngeal Carcinoma: NCT07752394 Clinical Landscape Report 2026
28 September 2026
NCT07752394 clinical landscape for Hypopharyngeal Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Finotonlimab in Squamous Cell Carcinoma of Head and Neck: NCT07751276 Clinical Landscape Report 2026
9 min read
Finotonlimab in Squamous Cell Carcinoma of Head and Neck: NCT07751276 Clinical Landscape Report 2026
28 September 2026
NCT07751276 clinical landscape for Squamous Cell Carcinoma of Head and Neck: endpoints, sponsor, phase, geography, readouts, asset context and development wh…
Read →
Semaglutide (Novo Nordisk) in Alcohol Use Disorder: NCT07772960 Clinical Landscape Report 2026
9 min read
Semaglutide (Novo Nordisk) in Alcohol Use Disorder: NCT07772960 Clinical Landscape Report 2026
28 September 2026
NCT07772960 clinical landscape for Alcohol Use Disorder: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Semaglutide (Novo Nordisk) in Obesity: NCT07754045 Clinical Landscape Report 2026
9 min read
Semaglutide (Novo Nordisk) in Obesity: NCT07754045 Clinical Landscape Report 2026
28 September 2026
NCT07754045 clinical landscape for Obesity: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
PP03A in Obesity: NCT07777575 Clinical Landscape Report 2026
9 min read
PP03A in Obesity: NCT07777575 Clinical Landscape Report 2026
28 September 2026
NCT07777575 clinical landscape for Obesity: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Zenagamtide in Weight Loss: NCT07757087 Clinical Landscape Report 2026
9 min read
Zenagamtide in Weight Loss: NCT07757087 Clinical Landscape Report 2026
28 September 2026
NCT07757087 clinical landscape for Weight Loss: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Oliceridine fumarate in Obesity: NCT07759778 Clinical Landscape Report 2026
9 min read
Oliceridine fumarate in Obesity: NCT07759778 Clinical Landscape Report 2026
28 September 2026
NCT07759778 clinical landscape for Obesity: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Ipilimumab in Locally Advanced Malignant Neoplasm: NCT07751055 Clinical Landscape Report 2026
9 min read
Ipilimumab in Locally Advanced Malignant Neoplasm: NCT07751055 Clinical Landscape Report 2026
28 September 2026
NCT07751055 clinical landscape for Locally Advanced Malignant Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development white s…
Read →
SHR-9839 in Advanced Esophageal Squamous Cell Carcinoma: NCT07751341 Clinical Landscape Report 2026
9 min read
SHR-9839 in Advanced Esophageal Squamous Cell Carcinoma: NCT07751341 Clinical Landscape Report 2026
28 September 2026
NCT07751341 clinical landscape for Advanced Esophageal Squamous Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development…
Read →
GLP-1 agonist (Nxera Pharma) in Arthritis: NCT07755085 Clinical Landscape Report 2026
9 min read
GLP-1 agonist (Nxera Pharma) in Arthritis: NCT07755085 Clinical Landscape Report 2026
28 September 2026
NCT07755085 clinical landscape for Arthritis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Semaglutide (Novo Nordisk) in Obesity: ACTRN12626001033336 Clinical Landscape Report 2026
9 min read
Semaglutide (Novo Nordisk) in Obesity: ACTRN12626001033336 Clinical Landscape Report 2026
28 September 2026
ACTRN12626001033336 clinical landscape for Obesity: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →